Praxis Precision Medicines announced that the FDA has extended the review period for its New Drug Application (NDA) for relutrigine, a treatment for SCN2A and SCN8A developmental and epileptic encephalopathies, by three months to December 27, 2026. This extension follows the submission of additional sensitivity analyses, classified as a major amendment by the FDA, allowing more time for review. No new clinical studies were requested, and no safety or manufacturing concerns were cited. Praxis remains confident in the application and is preparing to bring relutrigine to patients with significant unmet needs.
Plum Acquisition Corp. IV has postponed its extraordinary general meeting of shareholders from July 2 to July 10, 2026, to allow more time for shareholder engagement. Consequently, the deadline for shareholders to submit redemption requests has been ...
The U.S. Supreme Court ruled in Chatrie v. U.S. that government collection of location data via geofence warrants constitutes a search under the Fourth Amendment. This decision overturns a lower court ruling and requires further review of whether the...
DBV Technologies is preparing to submit a Biologics License Application (BLA) for its VIASKIN® Peanut patch aimed at children aged 4 to 7 years. The company has engaged in detailed discussions with the FDA to ensure a thorough and efficient review pr...
Bron, a self-custody crypto wallet provider, has partnered with Noah, a global stablecoin payments infrastructure company, to enable seamless on- and off-ramp access for stablecoins. This integration allows Bron users to easily fund and withdraw from...
Institutional investors have decreased their exposure to Bitcoin and Ethereum ETFs, signaling a shift in their cryptocurrency investment strategies. Despite this reduction, they continue to increase their investments in XRP and HYPE wrappers, which a...
